Deal Flow
Letter · prints on one page
Transaction tear sheetData as of Nov 7, 2026
M&A · Healthcare · Laboratory Analytical Instruments

Berkeley Lights, Inc. to acquire IsoPlexis Corp

Announced Dec 21, 2022 · Closed Mar 21, 2023

Deal value$58MEV $51M
Premium—To unaffected price
EV / Adj. EBITDA—2.7x EV / Revenue
ConsiderationAll stock$1.46 per share

Transaction

Acquirer
Berkeley Lights, Inc. (BLI)
Target
IsoPlexis Corp (ISO)
Buyer type
Strategic
Offer price per share
$1.46
Enterprise value
$51M
Status
Closed Mar 21, 2023

Deal protections

Break fee (target pays)
$2.3M · 4.0%
Reverse fee (buyer pays)
$2.3M · 4.0%
Go-shop
No-shop
Financing
—

Advisors

To the acquirer
TD Cowen
To the target
Evercore
TD Cowen fee
$3.0M
Evercore fee
$3.0M

Sector context · Healthcare

Comparable deals
73 in the prior 24 months
Premium
Sector median 47.5%
EV / Adj. EBITDA
Sector median 20.4x
Break fee
4.0% vs. 3.4% sector median

Timeline

  1. AnnouncedDec 21, 2022
  2. Proxy filedFeb 13, 2023
  3. Definitive proxyFeb 13, 2023
  4. Shareholder voteMar 16, 2023
  5. ClosedMar 21, 2023

Valuation · fairness opinions

Trading comparablesTD Cowen$0.93$2.65
Trading comparablesTD Cowen$1.16$3.73
Trading comparablesTD Cowen$1.53$4.06
Trading comparablesTD Cowen$4.07$9.05
Trading comparablesTD Cowen$3.94$9.49
Discounted cash flowEvercore$1.78$2.34
Discounted cash flowEvercore$2.67$3.36
Discounted cash flowEvercore$7.22$9.17
Future share priceEvercore$0.53$0.75
Future share priceEvercore$1.72$2.36
Offer $1.46

Implied value per IsoPlexis Corp share by analysis, from TD Cowen and Evercore.

Sources
  • 8-K (EX-99.1) · Dec 21, 2022
  • 425 (EX-99.1) · Dec 21, 2022
  • 425 (EX-99.1) · Dec 21, 2022

Adj. EBITDA is operating income + D&A + impairment, restructuring, deal costs and stock compensation, less any large gain on a sale, last twelve months, from the target's filings. Calculated by Castle, so it can differ from a bank's adjusted figure.

Prepared with Castle from public SEC EDGAR filings. Figures are extracted automatically; verify against the source documents. Not investment advice.